Additionally, a non-BRAF-mutant melanoma cell line (Ma-Mel-103b) was also studied in parallel, to identify the possible effects of vemurafenib, alone or in combination, on cells lacking the targeted mutation. This evidence concerns the gene BRAF and melanoma.